Olanzapine/samidorphan - Alkermes
Alternative Names: ALKS 33/olanzapine; ALKS-3831; LYBALVI; Olanzapine/ALKS 33; OLZ/SAM - Alkermes plc; Samidorphan/olanzapineLatest Information Update: 11 Aug 2026
At a glance
- Originator Alkermes plc
- Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Mood stabilisers; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Schizophrenia
- No development reported Psychotic disorders
Most Recent Events
- 29 Jul 2026 Alkermes initiates an Expanded Access Program for Schizophrenia and Bipolar disorder(In children, In adolescents) in USA (PO)(NCT07744113)
- 27 Feb 2026 Alkermes has patent protection for Olanzapine/samidorphan in USA
- 31 Jan 2025 Alkermes has patent protection for olanzapine/samidorphan in USA